In March 11th we wrote a detailed report on Teva Pharmaceutical Inc. (TEVA) [stock_quote symbol=”TEVA”]  titled: “Teva Pharmaceutical Inc. (TEVA): Possibly the most undervalued global pharmaceutical company“. Since, TEVA is up more than 30% and has outperformed the SPY by more than 35% since our initial report. Yesterday, we published an update indicating that TEVA’s bullish narrative continues and that our price target stands.

Shortly after release of our report, TEVA released news that they plan to present new data, including long-term data, at the 60th Annual Scientific Meeting of the American Headache Society which is taking place in San Francisco from June 28 – July 1st of 2018.

They are planning to present one-year data on Fremanezumab, which will include, long-term response rates, acute headache medication use, and disability, efficacy, safety, quality-of-life impact, and reversion of patients from chronic to episodic migraine. TEVA announced earlier that they will no longer be pursuing the chronic migraine market and are going to focus on the episodic instead.

Fremanezumab, is a humanized monoclonal antibody targeting calcitonin gene–related peptide (CGRP), is being investigated as a preventive treatment for migraine. Migraine is described as a complex neurological disorder that is characterized by recurrent pulsating headaches of at least moderate severity. It is estimated that there is a global prevalence of 15% – 18%. However, chronic migraine – occurrence of at least 15 days with headache per month for at least 3 months – effects approximately 2% of the population.

 

[finviz ticker=TEVA width=600]

 

About Teva Pharmaceuticals:

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams. This segment also develops, manufactures, and sells active pharmaceutical ingredients. The Specialty Medicines segment provides specialty medicines for use in central nervous system and respiratory indications. Its products in the central nervous system area comprise Copaxone for the treatment of relapsing forms of MS; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. This segment’s products in the respiratory market include ProAir, ProAir Respiclick, QVAR, Duoresp Spiromax, Qnasl, Braltus, Cinqair/Cinqaero, and Aerivio Spiromax for the treatment of asthma and chronic obstructive pulmonary disease, as well as Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim products in the oncology market. The company has collaboration arrangements with Otsuka Pharmaceutical Co. Ltd. and Regeneron Pharmaceuticals, Inc. Teva Pharmaceutical Industries Limited was founded in 1901 and is headquartered in Petach Tikva, Israel. [source: finviz.com]

Get posts delivered to your mailbox!

subscribe to our research

Subscribe to our research to gain access to our outstanding research articles covering both stocks and securities and blockchain and cryptocurrency. We do not publish frequent reports, however, the quality of our research is outstanding. Our readers can expect one to four research quality articles per month. Upon subscribing, members gain access to our extensive research on securities, blockchain projects and crypto assets. Our reports include details regarding, the demand and the market, roadmaps, strengths and weaknesses of the team and advisory board, key partnerships and associations, competitions and key concerns, tokens and supply – for blockchain projects.

[supsystic-price-table id=8]

 

Disclaimer: The above references an opinion and is for information purposes only.  It is not intended to be investment advice.  Seek a duly licensed professional for investment advice. The Author does not hold any of the securities discussed above.
Legal: The information contained on this site is provided for general informational purposes, as a convenience to the readers. The materials are not a substitute for obtaining professional advice from a qualified person, firm or corporation. Consult the appropriate professional advisor for more complete and current information. Point Pleasant Park Capital (“The Company”) does not engage in rendering any legal or professional services by placing these general informational materials on this website. The Company specifically disclaims any liability, whether based in contract, tort, strict liability or otherwise, for any direct, indirect, incidental, consequential, or special damages arising out of or in any way connected with access to or use of the site, even if I have been advised of the possibility of such damages, including liability in connection with mistakes or omissions in, or delays in transmission of, information to or from the user, interruptions in telecommunications connections to the site or viruses. The Company makes no warranties about the accuracy or completeness of the information contained on this website. Any links provided to other server sites are offered as a matter of convenience and in no way are meant to imply that The Company endorses, sponsors, promotes or is affiliated with the owners of or participants in those sites, or endorse any information contained on those sites, unless expressly stated.